ConductScience.org, home
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
API referenceFor AI assistants

Trial · NCT06548204

Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryLate gadolinium enhancement/Left ventricular mass (LGE/LV%)6 months after myocardial infarctionThe difference of LGE/LV% from baseline. LGE/LV% will be assessed by CMR.
SecondaryLeft ventricular ejection fraction (LVEF)6 months after myocardial infarctionThe difference of LVEF from baseline. LVEF will be assessed by CMR.
SecondaryLeft ventricular end-systolic volume/body surface area (LVESV/BSA%)6 months after myocardial infarctionThe difference of LVESV/BSA% from baseline. LVESV will be assessed by CMR and BSA will be calculated by height and weight.
SecondaryLeft ventricular end-diastolic volume/body surface area (LVEDV/BSA%)6 months after myocardial infarctionThe difference of LVEDV/BSA% from baseline. LVEDV will be assessed by CMR and BSA will be calculated by height and weight.
SecondaryLeft ventricular ejection fraction (LVEF)6 months after myocardial infarctionThe difference of LVEF from baseline. LVEF will be assessed by UCG.
SecondaryLeft ventricular end-systolic volume/body surface area (LVESV/BSA%)6 months after myocardial infarctionThe difference of LVESV/BSA% from baseline. LVESV will be assessed by UCG and BSA will be calculated by height and weight.
SecondaryLeft ventricular end-diastolic volume/body surface area (LVEDV/BSA%)6 months after myocardial infarctionThe difference of LVEDV/BSA% from baseline. LVEDV will be assessed by UCG and BSA will be calculated by height and weight.
SecondaryExtracellular volume (ECV)6 months after myocardial infarctionThe difference of ECV from baseline. ECV will be assessed by CMR.
SecondaryIntramyocardial hemorrhage (IMH)6 months after myocardial infarctionAnalysis of differences of IMH from baseline.
Secondarystroke volume6 months after myocardial infarctionAnalysis of differences of stroke volume from baseline.
Secondaryperi-infarct zone6 months after myocardial infarctionAnalysis of differences of peri-infarct zone from baseline.
SecondaryBNP6 months after myocardial infarctionAnalysis of differences of BNP from baseline.
SecondaryVO2 max6 months after myocardial infarctionAnalysis of VO2 max.
SecondarySAQ scale score6 months after myocardial infarctionAnalysis of SAQ scale score.
SecondaryDrug-associated adverse reaction1 month, 3 months and 6 months after myocardial infarctionHeart, nerve system, mental system, digestive system and immune system reactions.
SecondaryIncidence of MACE6 months after myocardial infarctionIncidence of Cardiac death, myocardial infarction and readmission due to heart failure.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06548204/registered

API referenceFor AI assistants